Decreased stathmin expression ameliorates neuromuscular defects but fails to prolong survival in a mouse model of spinal muscular atrophy

Neurobiology of Disease

Volumn 52, Issue , 2013, Pages 94-103

  Wen, Hsin Lan ^a   Ting, Chen Hung ^a   Liu, Huei Chun ^a,b   Li, Hung ^a   Lin Chao, Sue ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

STATHMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC CROSS; HETEROZYGOSITY; HOMOZYGOSITY; IN VIVO STUDY; MOTONEURON; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOUSE; NERVE CELL CULTURE; NEUROMUSCULAR SYNAPSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY; STATHMIN GENE; UPREGULATION; WEIGHT GAIN;

ANIMALS; AXONS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; LONGEVITY; MICE; MICE, KNOCKOUT; MICROTUBULES; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; STATHMIN; SURVIVAL OF MOTOR NEURON 1 PROTEIN; UP-REGULATION;

EID: 84873524314     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.11.015     Document Type: Article

References (59)

1. Araki S., et al. Neuropathological analysis in spinal muscular atrophy type II. Acta Neuropathol. 2003, 106:441-448.
2. Bevan A.K., et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 2010, 19:3895-3905.
3. Bolliger M.F., et al. Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction. J. Cell Sci. 2010, 123:3944-3955.
4. Bosch-Marce M., et al. Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum. Mol. Genet. 2011, 20:1844-1853.
5. Bowerman M., et al. Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J. Mol. Neurosci. 2007, 32:120-131.
6. Bowerman M., et al. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 2010, 19:1468-1478.
7. Brzustowicz L.M., et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990, 344:540-541.
8. Bsibsi M., et al. The microtubule regulator stathmin is an endogenous protein agonist for TLR3. J. Immunol. 2010, 184:6929-6937.
9. Bussaglia E., et al. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat. Genet. 1995, 11:335-337.
10. Chabas D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
11. Cifuentes-Diaz C., et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum. Mol. Genet. 2002, 11:1439-1447.
12. Clermont O., et al. SMN gene deletions in adult-onset spinal muscular atrophy. Lancet 1995, 346:1712-1713.
13. Coovert D.D., et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 1997, 6:1205-1214.
14. De Lella Ezcurra A.L., et al. Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis. 2010, 37:630-640.
15. Doye V., et al. A single cDNA encodes two isoforms of stathmin, a developmentally regulated neuron-enriched phosphoprotein. J. Biol. Chem. 1989, 264:12134-12137.
16. El-Khodor B.F., et al. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp. Neurol. 2008, 212:29-43.
17. Frugier T., et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 2000, 9:849-858.
18. Garcia-Cabezas M.A., et al. Neonatal spinal muscular atrophy with multiple contractures, bone fractures, respiratory insufficiency and 5q13 deletion. Acta Neuropathol. 2004, 107:475-478.
19. Gogliotti R.G., et al. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J. Neurosci. 2012, 32:3818-3829.
20. Hachiya Y., et al. Autonomic dysfunction in cases of spinal muscular atrophy type 1 with long survival. Brain Dev. 2005, 27:574-578.
21. Heier C.R., et al. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum. Mol. Genet. 2010, 19:3906-3918.
22. Hsieh-Li H.M., et al. A mouse model for spinal muscular atrophy. Nat. Genet. 2000, 24:66-70.
23. Hua Y., et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478:123-126.
24. Kaspar B.K., et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301:839-842.
25. Koppel J., et al. Developmental tissue expression and phylogenetic conservation of stathmin, a phosphoprotein associated with cell regulations. J. Biol. Chem. 1990, 265:3703-3707.
26. Kuru S., et al. An autopsy case of spinal muscular atrophy type III (Kugelberg-Welander disease). Neuropathology 2009, 29:63-67.
27. Larsson N., et al. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol. Cell. Biol. 1997, 17:5530-5539.
28. Lefebvre S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
29. Lefebvre S., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 1997, 16:265-269.
30. Liedtke W., et al. Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems. Am. J. Pathol. 2002, 160:469-480.
31. Liu Q., Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 1996, 15:3555-3565.
32. Liu Q., et al. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997, 90:1013-1021.
33. Liu A., et al. Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders. J. Neurosci. 2005, 25:737-747.
34. Lorson C.L., et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:6307-6311.
35. Marklund U., et al. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J. 1996, 15:5290-5298.
36. Marques M.J., et al. From plaque to pretzel: fold formation and acetylcholine receptor loss at the developing neuromuscular junction. J. Neurosci. 2000, 20:3663-3675.
37. McWhorter M.L., et al. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. 2003, 162:919-931.
38. Meister G., et al. SMNrp is an essential pre-mRNA splicing factor required for the formation of the mature spliceosome. EMBO J. 2001, 20:2304-2314.
39. Monani U.R., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8:1177-1183.
40. Monani U.R., et al. Animal models of spinal muscular atrophy. Hum. Mol. Genet. 2000, 9:2451-2457.
41. Nolle A., et al. The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum. Mol. Genet. 2011, 20:4865-4878.
42. Palazzolo I., et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
43. Papadimitriou D., et al. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol. Dis. 2010, 37:493-502.
44. Park K.W., et al. IL-13-induced oxidative stress via microglial NADPH oxidase contributes to death of hippocampal neurons in vivo. J. Immunol. 2009, 183:4666-4674.
45. Park G.H., et al. Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J. Neurosci. 2010, 30:12005-12019.
46. Pearn J. Classification of spinal muscular atrophies. Lancet 1980, 1:919-922.
47. Pellizzoni L., et al. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998, 95:615-624.
48. Pellizzoni L., et al. Essential role for the SMN complex in the specificity of snRNP assembly. Science 2002, 298:1775-1779.
49. Peschanski M., et al. Stathmin: cellular localization of a major phosphoprotein in the adult rat and human CNS. J. Comp. Neurol. 1993, 337:655-668.
50. Riessland M., et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 2010, 19:1492-1506.
51. Ringhoff D.N., Cassimeris L. Gene expression profiles in mouse embryo fibroblasts lacking stathmin, a microtubule regulatory protein, reveal changes in the expression of genes contributing to cell motility. BMC Genomics 2009, 10:343.
52. Rossoll W., et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J. Cell Biol. 2003, 163:801-812.
53. Rudnik-Schoneborn S., et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J. Med. Genet. 2008, 45:635-638.
54. Tanaka H., et al. Myocardial ultrastructural changes in Kugelberg-Welander syndrome. Br. Heart J. 1977, 39:1390-1393.
55. Ting C.H., et al. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum. Mol. Genet. 2007, 16:499-514.
56. Torres-Benito L., et al. SMN requirement for synaptic vesicle, active zone and microtubule postnatal organization in motor nerve terminals. PLoS One 2011, 6:e26164.
57. Wen H.L., et al. Stathmin, a microtubule-destabilizing protein, is dysregulated in spinal muscular atrophy. Hum. Mol. Genet. 2010, 19:1766-1778.
58. Zhang Z., et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008, 133:585-600.
59. Zhao F., et al. Manganese induces dopaminergic neurodegeneration via microglial activation in a rat model of manganism. Toxicol. Sci. 2009, 107:156-164.